Stacey Jenkins - Musclepharm Corp Director
| MSLPDelisted Stock | USD 0 0.0002 15.38% |
Director
Mr. Stacey Jenkins is Director of MusclePharm Corporationrationration. Mr. Jenkins currently serves as a senior attorney with Medicity Inc. a global leader in healthcare enablement software and services where he focuses upon contract negotiation technology and communication and regulatory matters. Prior to joining Medicity Inc. Mr. Jenkins focused on his private practice providing general corporate legal services securities guidance human resources consulting and litigation support. From 2010 to 2012 Mr. Jenkins served as General Counsel for Opinionology Inc. an online global data collection and survey company where he focused on contract negotiation telecommunications regulatory issues and complex HR issues. Additionally he helped prepare and guide Opinionology through a merger with Sampling International. Prior to joining Opinionology Jenkins developed his own legal private practice and consultancy providing corporate guidance and oversight as well as technology assistance to struggling companies. Prior to his private practice Jenkins managed IT infrastructure for Moen Faucets. Mr. Jenkins years of experience and grasp of regulatory and corporate governance issues as well as his contract negotiation human resources and technology background provide ideal expertise to join the Companys Board. Mr. Jenkins received his law degree from the University of Utah SJ Quinney College of Law and attended college at Montana State University and the University of Phoenix. since 2015.
| Tenure | 9 years |
| Phone | 800 859 3010 |
| Web | https://www.musclepharm.com |
Musclepharm Corp Management Efficiency
The company has return on total asset (ROA) of (0.665) % which means that it has lost $0.665 on every $100 spent on assets. This is way below average. Musclepharm Corp's management efficiency ratios could be used to measure how well Musclepharm Corp manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.64 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. Musclepharm Corp has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Musclepharm Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Musclepharm Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Musclepharm Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Musclepharm to invest in growth at high rates of return. When we think about Musclepharm Corp's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Karen McGinnis | Alphatec Holdings | 51 | |
| CGMA CPA | Glacier Bancorp | N/A | |
| Joseph Galante | Cumberland Pharmaceuticals | 68 | |
| Douglas McBride | Glacier Bancorp | 68 | |
| Thomas Gunderson | Merit Medical Systems | 66 | |
| Caroline Young | Cumberland Pharmaceuticals | N/A | |
| Martin Madden | Microbot Medical | 57 | |
| Jill Anderson | Merit Medical Systems | 58 | |
| George Sutton | Glacier Bancorp | 72 | |
| F Millner | Merit Medical Systems | N/A | |
| Yoav Waizer | Microbot Medical | 51 | |
| Jason Hochberg | Alphatec Holdings | N/A | |
| James Jones | Cumberland Pharmaceuticals | 67 | |
| lan Molson | Alphatec Holdings | 61 | |
| Ann Millner | Merit Medical Systems | 65 | |
| Moshe Shoham | Microbot Medical | 64 | |
| Scott Burell | Microbot Medical | 52 | |
| R Molson | Alphatec Holdings | 59 | |
| Michael Bonner | Cumberland Pharmaceuticals | N/A | |
| Annie Goodwin | Glacier Bancorp | 62 | |
| David Boyles | Glacier Bancorp | 70 | |
Management Performance
| Return On Asset | -0.66 |
Musclepharm Corp Leadership Team
Elected by the shareholders, the Musclepharm Corp's board of directors comprises two types of representatives: Musclepharm Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Musclepharm. The board's role is to monitor Musclepharm Corp's management team and ensure that shareholders' interests are well served. Musclepharm Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Musclepharm Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Lynch, CFO, Principal Financial Officer, Principal Accounting Officer | ||
| Gary Shirshac, Interim Officer | ||
| William Bush, Director | ||
| Moore DSc, Chief Board | ||
| Stacey Jenkins, Director | ||
| Noel Thompson, Independent Director | ||
| Michael Doron, Independent Director | ||
| Brad Pyatt, Chairman of the Board, CEO | ||
| Matthew Kerbel, Chief Marketing Officer | ||
| Alberto Andrade, COO | ||
| Brian Cavanaugh, Senior Vice President - Retail and Brand Strategy | ||
| Brian Casutto, Executive Vice President - Sales and Operations, Director | ||
| John Price, CFO | ||
| Ryan Drexler, Executive Chairman | ||
| Mark Groussman, Consultant | ||
| Douglas West, Interim Principal Financial Officer, Interim Principal Accounting Officer | ||
| John Mills, Sr. Managing Director | ||
| John Desmond, Independent Director | ||
| Eric Chin, Chief Director |
Musclepharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Musclepharm Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.66 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.23) % | |||
| Current Valuation | 22.12 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 53.50 % | |||
| Shares Owned By Institutions | 15.05 % | |||
| Price To Sales | 0 X | |||
| Revenue | 50.04 M | |||
| Gross Profit | 5.37 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Musclepharm Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Musclepharm Corp's short interest history, or implied volatility extrapolated from Musclepharm Corp options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Musclepharm Pink Sheet
If you are still planning to invest in Musclepharm Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Musclepharm Corp's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |